Literature DB >> 22571695

Implication of microRNAs in the pathogenesis of MDS.

Jing Fang1, Melinda Varney, Daniel T Starczynowski.   

Abstract

MicroRNAs (miRNAs) are significant regulators of human hematopoietic stem cells (HSC), and their deregulation contributes to hematological malignancies. Myelodysplastic syndromes (MDS) represent a spectrum of hematological disorders characterized by dysfunctional HSC, ineffective blood cell production, progressive marrow failure, and an increased risk of developing acute myeloid leukemia (AML). Although miRNAs have been primarily studied in AML, only recently have similar studies been performed on MDS. In this review, we describe the normal function and expression of miRNAs in human HSC, and describe mounting evidence that deregulation of miRNAs contributes to the pathogenesis of MDS.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22571695      PMCID: PMC4863958          DOI: 10.2174/1381612811209023170

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  106 in total

1.  MicroRNA genes are transcribed by RNA polymerase II.

Authors:  Yoontae Lee; Minju Kim; Jinju Han; Kyu-Hyun Yeom; Sanghyuk Lee; Sung Hee Baek; V Narry Kim
Journal:  EMBO J       Date:  2004-09-16       Impact factor: 11.598

2.  MicroRNA expression profiles in umbilical cord blood cell lineages.

Authors:  Michaela Merkerova; Alzbeta Vasikova; Monika Belickova; Hana Bruchova
Journal:  Stem Cells Dev       Date:  2010-01       Impact factor: 3.272

3.  Diagnostic microRNAs in myelodysplastic syndrome.

Authors:  Begum Erdogan; Crystal Facey; Julianne Qualtieri; Jason Tedesco; Elizabeth Rinker; R Benjamin Isett; John Tobias; Donald A Baldwin; James E Thompson; Martin Carroll; Annette S Kim
Journal:  Exp Hematol       Date:  2011-06-15       Impact factor: 3.084

4.  Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

Authors:  Alan List; Gordon Dewald; John Bennett; Aristotle Giagounidis; Azra Raza; Eric Feldman; Bayard Powell; Peter Greenberg; Deborah Thomas; Richard Stone; Craig Reeder; Kenton Wride; John Patin; Michele Schmidt; Jerome Zeldis; Robert Knight
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

5.  NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses.

Authors:  Konstantin D Taganov; Mark P Boldin; Kuang-Jung Chang; David Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-02       Impact factor: 11.205

Review 6.  Are we nearer to curing patients with MDS?

Authors:  Mikkael A Sekeres
Journal:  Best Pract Res Clin Haematol       Date:  2010-11-01       Impact factor: 3.020

7.  Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers.

Authors:  George Adrian Calin; Cinzia Sevignani; Calin Dan Dumitru; Terry Hyslop; Evan Noch; Sai Yendamuri; Masayoshi Shimizu; Sashi Rattan; Florencia Bullrich; Massimo Negrini; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-18       Impact factor: 11.205

8.  Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia.

Authors:  Véronique Gelsi-Boyer; Virginie Trouplin; José Adélaïde; Julien Bonansea; Nathalie Cervera; Nadine Carbuccia; Arnaud Lagarde; Thomas Prebet; Meyer Nezri; Danielle Sainty; Sylviane Olschwang; Luc Xerri; Max Chaffanet; Marie-Joëlle Mozziconacci; Norbert Vey; Daniel Birnbaum
Journal:  Br J Haematol       Date:  2009-04-15       Impact factor: 6.998

9.  Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin.

Authors:  Ramiro Garzon; Michela Garofalo; Maria Paola Martelli; Roger Briesewitz; Lisheng Wang; Cecilia Fernandez-Cymering; Stefano Volinia; Chang-Gong Liu; Susanne Schnittger; Torsten Haferlach; Arcangelo Liso; Daniela Diverio; Marco Mancini; Giovanna Meloni; Robin Foa; Massimo F Martelli; Cristina Mecucci; Carlo M Croce; Brunangelo Falini
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-28       Impact factor: 11.205

10.  Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes.

Authors:  Azim Mohamedali; Joop Gäken; Natalie A Twine; Wendy Ingram; Nigel Westwood; Nicholas C Lea; Janet Hayden; Nora Donaldson; Carlo Aul; Norbert Gattermann; Aristotle Giagounidis; Ulrich Germing; Alan F List; Ghulam J Mufti
Journal:  Blood       Date:  2007-07-18       Impact factor: 22.113

View more
  5 in total

1.  A 4-lncRNA scoring system for prognostication of adult myelodysplastic syndromes.

Authors:  Chi-Yuan Yao; Ching-Hsuan Chen; Huai-Hsuan Huang; Hsin-An Hou; Chien-Chin Lin; Mei-Hsuan Tseng; Chein-Jun Kao; Tzu-Pin Lu; Wen-Chien Chou; Hwei-Fang Tien
Journal:  Blood Adv       Date:  2017-08-16

Review 2.  Hematopoietic Cell Transplantation for Older Patients with MDS.

Authors:  Mazyar Shadman; H Joachim Deeg
Journal:  Mediterr J Hematol Infect Dis       Date:  2014-09-01       Impact factor: 2.576

Review 3.  MicroRNA, an Antisense RNA, in Sensing Myeloid Malignancies.

Authors:  Stephanie Rebecca Setijono; Hyog Young Kwon; Su Jung Song
Journal:  Front Oncol       Date:  2018-01-30       Impact factor: 6.244

4.  Targeting miR-126 disrupts maintenance of myelodysplastic syndrome stem and progenitor cells.

Authors:  Huafeng Wang; Jie Sun; Bin Zhang; Dandan Zhao; Hongyan Tong; Herman Wu; Xia Li; Yingwan Luo; Dan Dong; Yiyi Yao; Tinisha McDonald; Anthony S Stein; Monzr M Al Malki; Flavia Pichiorri; Nadia Carlesso; Ya-Huei Kuo; Guido Marcucci; Ling Li; Jie Jin
Journal:  Clin Transl Med       Date:  2021-10

5.  Microvesicles from Mesenchymal Stromal Cells Are Involved in HPC-Microenvironment Crosstalk in Myelodysplastic Patients.

Authors:  Sandra Muntión; Teresa L Ramos; María Diez-Campelo; Beatriz Rosón; Luis Ignacio Sánchez-Abarca; Irena Misiewicz-Krzeminska; Silvia Preciado; María-Eugenia Sarasquete; Javier de Las Rivas; Marcos González; Fermín Sánchez-Guijo; María-Consuelo Del Cañizo
Journal:  PLoS One       Date:  2016-02-02       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.